Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i><sup>+</sup> advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.Frontiers in Oncology|March 16, 2023
Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospitalSandra Pinet, Stéphanie Durand, Alexandre Perani, et al.The Lancet. Oncology|September 5, 2020
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trialNathalie Baize, Isabelle Monnet, Laurent Greillier, et al.The New England Journal of Medicine|September 30, 2020
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLCRoy S Herbst, Giuseppe Giaccone, Filippo de Marinis, et al.Lung Cancer (Amsterdam, Netherlands)|July 14, 2024
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study)Mathilde Jacob, Pierre Fournel, Claire Tissot, et al.The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.JAMA Oncology|July 17, 2015
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC TrialNiki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt, et al.Scientific Reports|December 8, 2015
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerNiki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2021
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialLuis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.Journal of the National Cancer Institute|April 5, 2017
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLCImane Chaib, Niki Karachaliou, Sara Pilotto, et al.Pageof 6